Today’s Stock picks are two Speculative Biotech Stocks, Entera Bio (ENTX) which closed Friday, September 18, 2026 at $2.96 and Fate Therapeutics which closed at $2.53.
Nothing I say in this article is Investment Advice. For Investment Advice, contact a Registered Investment Advisor, or Certified Financial Planner.
Biotech Stocks can be very risky investments, and if the company has a drug in clinical trials, and the drug doesn’t pass muster with the FDA, you can lose all or a large part of your investment. It happened to me years ago on a stock that I had picked for my subscribers and also bought myself. I lost about $5,000 in 3 days. So I am cautious when buying any small Biotech’s stock. Always go to Finviz.com to read up on the company: What the analyst’s ratings are, Do they have enough cash on hand to get thru the clinical trials, Are Insiders buying or selling, What percentage of the company is owned by Management, How are the company’s drugs progressing in their clinical trials, etc. If a major brokerage house gave the stock a strong rating, you can assume that they have analyzed it thoroughly, which helps mediate the risk. But, I have seen drugs in trials that appeared to be slam dunks for approval by the FDA, NOT get approved by them.
ENTERA BIO (Symbol ENTX) $2.96. Entera is a BIG DEAL. They have a drug in clinical trials that is an oral drug, instead of one that requires an injection to treat osteoporosis. Osteoporosis treatments split into two categories: anti-resorptive drubs that slow bone loss, and anabolic drugs that actually rebuild bone and improve our skeleton, typically reserved for higher-risk patients. Every anabolic approved in the United States today, Eli Lilly’s Forteo, Paratek’s Tymlos, and Amgen’s Evenity, is delivered by injection. Forteo and Tynlos are self administered daily, and Evenity is administered twice a month by a healthcare provider.
Evenity generated close to $2.1 billion in 2025 sales despite the injection, cost and in-office visit burden. Entera’s drug delivers the identical bone-building peptide used in Forteo, which generated
approximately $1.6 billion in peak annual sales. So you would think that Entera’s drug would also be a Billion Dollar Blockbuster Drug if it gets approved…..and the stock could skyrocket.
If you look at the chart, you can see it more than tripled from late June to early August, and then made a Consolidation Triangle. It is still above its 50-Day Moving Average of 2.79. We think it will cross above the top trendline of that Triangle this week and be on the move again.
Leerink gave it a Buy Rating on September 18, with a Target Price of $9.00. Per Finviz.com, there are 173.83 Million shares outstanding, and a Float of 131.65 Million. They show earnings of -.35 per share and next years loss is estimated at -.46 per share. Insiders own 24.27% and no Insider selling is shown. We like the stock, and think it’s going a lot higher.
FATE THERAPEUTICS (Symbol FATE) $2.53. The company has CAR T off the shelf drug candidates. Its FT839 candidate is engineered to eliminate a broader range of disease driving immune cells compared to existing single-target CAR T therapies.ie., systemic lupus, rheumatoid arthritis, systemic sclerosis, etc.
If you look at the chart, you can see it made a big up-move in late June up to about $3.20 and then made a consolidation triangle. It broke above the down trendline of that triangle last week on big volume, and we expect it to cross back above its 50-Day Moving Average of 2.55 this week or next, and move up strongly. Jefferies gave it a Buy rating on May 19th, with a $5.00 price target. Per Finviz.com, there are 116.69 million shares outstanding, and Insiders own 4.67% of the stock. They show a loss of -$1.05 per share, and an estimated loss of -$1.05 per share next year. Insider Selling is minimal. We own the stock, and think it’s going a lot higher.
This article is not investment advice and it is not in any way to be construed as investment advice. For Investment Advice consult a Registered Investment Advisor or a Certified Financial Planner. Joe Cotton’s website is www.cottonstocks.net.
Returning as a columnist for the NKyTribune, Cotton is publisher of the market newsletter, Cotton’s Technically Speaking. He is a graduate of Xavier University, a former bank manager and credit analyst, and a former Fidelity Investments registered investment representative. Contact him at cottonstocks@hotmail.com